HC Wainwright Issues Pessimistic Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price

BioMarin Pharmaceutical (NASDAQ:BMRN) had its target price lowered by equities research analysts at HC Wainwright from $60.00 to $55.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. HC Wainwright’s price target points to a potential downside of 10.00% from the stock’s previous close.

A number of other research analysts also recently weighed in on BMRN. Wells Fargo & Company increased their target price on shares of BioMarin Pharmaceutical from $70.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Stifel Nicolaus set a $68.00 price objective on BioMarin Pharmaceutical in a report on Tuesday. Weiss Ratings reissued a “sell (d)” rating on shares of BioMarin Pharmaceutical in a research report on Monday, December 29th. Oppenheimer dropped their price target on BioMarin Pharmaceutical from $98.00 to $95.00 and set an “outperform” rating on the stock in a research report on Tuesday. Finally, Sanford C. Bernstein decreased their price objective on BioMarin Pharmaceutical from $95.00 to $88.00 and set an “outperform” rating for the company in a report on Monday, November 3rd. Fifteen equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $87.71.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ:BMRN opened at $61.11 on Wednesday. The company has a market capitalization of $11.74 billion, a P/E ratio of 34.33, a price-to-earnings-growth ratio of 0.52 and a beta of 0.26. The company’s 50-day moving average is $58.90 and its 200 day moving average is $56.15. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.10 and a current ratio of 5.21. BioMarin Pharmaceutical has a fifty-two week low of $50.76 and a fifty-two week high of $73.51.

Insider Buying and Selling

In other BioMarin Pharmaceutical news, EVP Gregory R. Friberg sold 6,326 shares of BioMarin Pharmaceutical stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $60.38, for a total transaction of $381,963.88. Following the completion of the transaction, the executive vice president owned 37,578 shares of the company’s stock, valued at $2,268,959.64. The trade was a 14.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.85% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of institutional investors and hedge funds have recently modified their holdings of the company. NewEdge Advisors LLC lifted its stake in BioMarin Pharmaceutical by 11.5% in the 1st quarter. NewEdge Advisors LLC now owns 3,769 shares of the biotechnology company’s stock worth $266,000 after purchasing an additional 388 shares in the last quarter. Empowered Funds LLC grew its position in BioMarin Pharmaceutical by 207.4% during the first quarter. Empowered Funds LLC now owns 12,023 shares of the biotechnology company’s stock worth $850,000 after buying an additional 8,112 shares in the last quarter. Focus Partners Wealth increased its stake in BioMarin Pharmaceutical by 70.2% in the 1st quarter. Focus Partners Wealth now owns 11,817 shares of the biotechnology company’s stock worth $835,000 after acquiring an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC raised its holdings in shares of BioMarin Pharmaceutical by 33.0% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,439 shares of the biotechnology company’s stock valued at $244,000 after acquiring an additional 1,102 shares in the last quarter. Finally, D.A. Davidson & CO. boosted its position in shares of BioMarin Pharmaceutical by 4.9% during the 2nd quarter. D.A. Davidson & CO. now owns 7,119 shares of the biotechnology company’s stock valued at $391,000 after acquiring an additional 331 shares during the last quarter. 98.71% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Wells Fargo called BMRN an attractive buy ahead of the Transcon‑CNP PDUFA, signaling investor interest around the upcoming regulatory decision. Wells Fargo Buy Note
• Positive Sentiment: Sanford C. Bernstein raised its price target from $90 to $94 and kept an outperform rating — a direct positive signal from a major sell‑side shop. Bernstein PT Raise (Benzinga)
• Positive Sentiment: Analysis pieces argue that recent share rebound and DCF assumptions may still imply upside for BMRN, supporting a constructive view for longer‑term investors. Pricing / DCF Upside Analysis
• Neutral Sentiment: Analysts broadly revised forecasts after Q4 results; the coverage is mixed and driving headline activity but not a uniform consensus. Analyst Revisions (Benzinga)
• Neutral Sentiment: BioMarin’s Q4 earnings call highlights were released; investors will parse guidance and R&D updates for implications on cash runway and upcoming catalysts. Q4 Earnings Call Highlights
• Neutral Sentiment: Short‑interest reports flagged a “large increase,” but the filings in the feed show inconsistent/zero values (NaN/0), making the short‑interest signal unreliable for now; not a clear driver.
• Negative Sentiment: HC Wainwright cut its price target to $55 and moved to a neutral rating, a downgrade that reduces near‑term sentiment given the lower target relative to recent levels. HC Wainwright PT Cut (Benzinga)
• Neutral Sentiment: Guggenheim trimmed its target from $106 to $86 but kept a buy rating; Oppenheimer also lowered its target to $95 — mixed signals that compress consensus and increase short‑term volatility. Guggenheim / Oppenheimer Coverage (Benzinga / AmericanBankingNews) Read More.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.